AR070063A1 - Uso de cannabinoides combinados con un medicamento antipsicotico y metodos de tratamiento - Google Patents
Uso de cannabinoides combinados con un medicamento antipsicotico y metodos de tratamientoInfo
- Publication number
- AR070063A1 AR070063A1 ARP080105764A ARP080105764A AR070063A1 AR 070063 A1 AR070063 A1 AR 070063A1 AR P080105764 A ARP080105764 A AR P080105764A AR P080105764 A ARP080105764 A AR P080105764A AR 070063 A1 AR070063 A1 AR 070063A1
- Authority
- AR
- Argentina
- Prior art keywords
- antipsychotic
- acid
- phytocannabinoids
- medicinal
- treatment methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0800390A GB2456183A (en) | 2008-01-04 | 2008-01-04 | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070063A1 true AR070063A1 (es) | 2010-03-10 |
Family
ID=39144704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105764A AR070063A1 (es) | 2008-01-04 | 2008-12-29 | Uso de cannabinoides combinados con un medicamento antipsicotico y metodos de tratamiento |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9017737B2 (enExample) |
| EP (3) | EP2249848B1 (enExample) |
| JP (1) | JP5409650B2 (enExample) |
| KR (1) | KR101631518B1 (enExample) |
| CN (1) | CN101939017B (enExample) |
| AR (1) | AR070063A1 (enExample) |
| AU (1) | AU2008346285B2 (enExample) |
| BR (1) | BRPI0821461A8 (enExample) |
| CA (1) | CA2708921C (enExample) |
| CL (1) | CL2008003902A1 (enExample) |
| CO (1) | CO6290695A2 (enExample) |
| ES (3) | ES2574155T3 (enExample) |
| GB (3) | GB2456183A (enExample) |
| HU (2) | HUE047214T2 (enExample) |
| IL (1) | IL206784A0 (enExample) |
| MX (1) | MX2010007073A (enExample) |
| NZ (1) | NZ586648A (enExample) |
| PE (2) | PE20091361A1 (enExample) |
| PL (2) | PL2609928T3 (enExample) |
| PT (2) | PT2609928T (enExample) |
| RU (1) | RU2503448C2 (enExample) |
| TW (2) | TWI519299B (enExample) |
| UA (1) | UA103472C2 (enExample) |
| WO (1) | WO2009087351A1 (enExample) |
| ZA (1) | ZA201005443B (enExample) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053092B2 (en) * | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| GB2377218A (en) * | 2001-05-04 | 2003-01-08 | Gw Pharmaceuticals Ltd | Process and apparatus for extraction of active substances and enriched extracts from natural products |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| CA2586358C (en) | 2004-11-16 | 2015-11-24 | Gw Pharma Limited | Use of tetrahydrocannabivarin (thcv) as neutral antagonist of the cb1 cannabinoid receptor |
| GB2459637B (en) * | 2008-01-21 | 2012-06-06 | Gw Pharma Ltd | New use for cannabinoids |
| GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| GB2478595B (en) * | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| JP5575324B2 (ja) * | 2010-03-26 | 2014-08-20 | ビバセル バイオテクノロジイ エスパーニャ、エス．エル | カンナビノイド・キノン誘導体 |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| US8445034B1 (en) | 2010-11-02 | 2013-05-21 | Albert L Coles, Jr. | Systems and methods for producing organic cannabis tincture |
| CA3114582A1 (en) | 2010-12-22 | 2012-06-28 | Syqe Medical Ltd. | Method and system for drug delivery |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| JP6562912B2 (ja) * | 2013-06-26 | 2019-08-21 | アムジェン インコーポレイテッド | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| CN105848646B (zh) | 2013-10-29 | 2019-10-22 | 艾克制药有限公司 | 包含大麻二酚的压制片剂、其制造方法以及此类片剂在口服治疗精神病症或焦虑症中的用途 |
| CN105873566B (zh) | 2013-10-29 | 2019-06-07 | 艾克制药有限公司 | 含有δ9-四氢大麻酚的压制片剂、其制造方法及此类片剂在口服治疗中的用途 |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| IL285915B (en) | 2014-06-30 | 2022-07-01 | Syqe Medical Ltd | Medicine cartridge for inhaler |
| AU2015283590B2 (en) | 2014-06-30 | 2020-04-16 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
| IL294077A (en) | 2014-06-30 | 2022-08-01 | Syqe Medical Ltd | Method and device for vaporizing and inhaling substances |
| KR102459896B1 (ko) * | 2014-06-30 | 2022-10-27 | 사이키 메디컬 엘티디. | 활성제의 폐 전달을 위한 방법, 디바이스 및 시스템 |
| US11298477B2 (en) | 2014-06-30 | 2022-04-12 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
| MX378842B (es) | 2014-06-30 | 2025-03-10 | Syqe Medical Ltd | Dispositivo inhalador con regulacion de flujo. |
| WO2016001924A2 (en) | 2014-06-30 | 2016-01-07 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| US9539295B2 (en) | 2014-12-05 | 2017-01-10 | Bradley Michael Bohus | Cannabidiol (CBD) enriched alcohol |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2542155B (en) * | 2015-09-09 | 2018-08-01 | Gw Pharma Ltd | Use of cannabidiol in the treatment of mental disorders |
| KR20180095674A (ko) | 2015-12-22 | 2018-08-27 | 조게닉스 인터내셔널 리미티드 | 대사 저항성 펜플루라민 유사체 및 그 사용 방법 |
| SG11201804811WA (en) | 2015-12-22 | 2018-07-30 | Zogenix International Ltd | Fenfluramine compositions and methods of preparing the same |
| AU2017204945B2 (en) | 2016-01-06 | 2022-11-10 | Syqe Medical Ltd. | Low dose therapeutic treatment |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
| JP2019524655A (ja) | 2016-06-29 | 2019-09-05 | キャンサイエンス イノベーションズ インコーポレーテッドＣａｎｎｓｃｉｅｎｃｅ Ｉｎｎｏｖａｔｉｏｎｓ Ｉｎｃ． | 脱炭酸大麻樹脂、その使用、及びそれを製造する方法 |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| US20180021326A1 (en) | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| US20210069170A1 (en) | 2016-07-23 | 2021-03-11 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
| US11701348B1 (en) | 2016-07-23 | 2023-07-18 | Turtle Bear Holdings, Llc | Psilocybin compositions |
| RU2746000C2 (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| CA3077624A1 (en) | 2016-10-01 | 2018-04-05 | James Smeeding | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
| CN108078984B (zh) * | 2016-11-23 | 2020-11-20 | 汉义生物科技（北京）有限公司 | 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用 |
| CN108143726B (zh) * | 2016-12-02 | 2020-05-08 | 汉义生物科技（北京）有限公司 | 大麻二酚与5-ht2a受体拮抗剂及5-ht再摄取抑制剂的药物组合物及其用途 |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| CA3047451A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| CA3047354A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| US12414936B2 (en) | 2017-02-09 | 2025-09-16 | Caamtech, Inc. | Compositions comprising a serotonergic tryptamine compound |
| US20190142851A1 (en) * | 2017-11-16 | 2019-05-16 | CaaMTech, LLC | Compositions comprising a psilocybin derivative and a cannabinoid |
| US11974984B2 (en) | 2017-02-09 | 2024-05-07 | Caamtech, Inc. | Compositions and methods comprising a combination of serotonergic drugs |
| JP7273731B2 (ja) * | 2017-02-09 | 2023-05-15 | カームテック、エルエルシー | シロシビン誘導体を含む組成物及び方法 |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| CN110799180A (zh) | 2017-06-26 | 2020-02-14 | 罗曼治疗系统股份公司 | 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统 |
| CN107469087A (zh) * | 2017-09-10 | 2017-12-15 | 孙永丽 | 用于治疗精神病的制剂 |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US10377708B2 (en) | 2017-12-05 | 2019-08-13 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| AU2018379992B2 (en) | 2017-12-05 | 2022-07-21 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| KR102332631B1 (ko) * | 2018-02-20 | 2021-12-01 | 엠와이엠디 파마슈티컬스 (플로리다), 인코포레이티드 | 물질 중독 및 다른 장애 치료용 유전자 변형 칸나비스 사티바 식물 및 변형된 칸나비노이드 화합물 |
| JP2021526507A (ja) | 2018-05-11 | 2021-10-07 | ゾゲニクス インターナショナル リミテッド | 発作により誘発される突然死を処置するための組成物および方法 |
| US12329862B2 (en) | 2018-06-20 | 2025-06-17 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| BR112020026099A2 (pt) | 2018-06-20 | 2021-03-23 | Lts Lohmann Therapie-Systeme Ag | sistema terapêutico transdérmico que contém asenapina |
| US12144787B2 (en) | 2018-11-19 | 2024-11-19 | Zogenix International Limited | Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5) |
| WO2020188569A1 (en) * | 2019-03-20 | 2020-09-24 | Bol Pharma Ltd. | Methods and compositions for preventing or treating weight gain caused by psychiatric drugs |
| US11160758B2 (en) | 2019-06-04 | 2021-11-02 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| GB201910389D0 (en) | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
| GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| CA3158059A1 (en) | 2019-11-19 | 2021-05-27 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| EP4188090A4 (en) | 2020-07-28 | 2024-08-14 | Impello Biosciences, Inc. | METHODS AND COMPOSITIONS FOR MODIFYING SECONDARY METABOLITES IN PLANTS |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| WO2022103635A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| US11337934B1 (en) | 2021-04-08 | 2022-05-24 | Lanny Leo Johnson | Compositions including a cannabinoid and protocatechuic acid |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| IL136839A (en) * | 2000-06-16 | 2006-12-10 | Yissum Res Dev Co | Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same |
| AR032641A1 (es) | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| EP1373216B1 (en) * | 2001-03-22 | 2004-12-15 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity |
| MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| CA2480856A1 (en) * | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Substituted aryl amides |
| DE10226494A1 (de) * | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
| GB2392093B (en) * | 2002-08-14 | 2006-03-08 | Gw Pharma Ltd | Pharmaceutical formulations |
| GB0222077D0 (en) | 2002-09-23 | 2002-10-30 | Gw Pharma Ltd | Methods of preparing cannabinoids from plant material |
| WO2004060374A1 (en) | 2002-12-27 | 2004-07-22 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
| CN102000336A (zh) * | 2003-05-23 | 2011-04-06 | 大塚制药株式会社 | 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂 |
| EP1644349B1 (en) * | 2003-06-24 | 2014-04-09 | GW Pharma Limited | Pharmaceutical compositions comprising cabbinochreme type compounds |
| CA2537535A1 (en) * | 2003-09-02 | 2005-03-10 | Solvay Pharmaceuticals Gmbh | Novel medical use of selective cb1-receptor antagonists |
| AU2004273865A1 (en) * | 2003-09-18 | 2005-03-31 | Merck & Co., Inc. | Substituted sulfonamides |
| SA04250288B1 (ar) * | 2003-09-19 | 2008-07-19 | سولفاي فارماسوتيكالز بي . في | مشتقات ثيازول thiazole كمعدلات لمستقبل المكونات الكيميائية للقنب cannabinoid |
| BRPI0417771A (pt) * | 2003-12-19 | 2007-04-17 | Bristol Myers Squibb Co | heterociclos azabicìclicos como moduladores de receptor canabinóides |
| WO2006017892A1 (en) * | 2004-08-16 | 2006-02-23 | Northern Sydney And Central Coast Area Health Service | Methods for improving cognitive functioning |
| GB0425248D0 (en) * | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| CA2586358C (en) * | 2004-11-16 | 2015-11-24 | Gw Pharma Limited | Use of tetrahydrocannabivarin (thcv) as neutral antagonist of the cb1 cannabinoid receptor |
| FR2882931B1 (fr) * | 2005-03-14 | 2007-05-18 | Sanofi Aventis Sa | Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique |
| DOP2006000273A (es) | 2005-12-08 | 2007-10-15 | Aventis Pharma Inc | Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia |
| EP2019593A4 (en) * | 2006-05-15 | 2010-10-27 | Merck Sharp & Dohme | PROTRUGS OF TERTIARY ALCOHOLS |
| GB2438682A (en) * | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
| EP1867308B1 (en) | 2006-06-12 | 2010-10-20 | Camp Scandinavia Ab | Frame for a hyperextension brace |
| US8481085B2 (en) * | 2006-06-15 | 2013-07-09 | Gw Pharma Limited | Pharmaceutical compositions comprising cannabigerol |
| GB2439393B (en) * | 2006-06-23 | 2011-05-11 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
| TW200848063A (en) * | 2007-04-23 | 2008-12-16 | Combinatorx Inc | Methods and compositions for the treatment of neurodegenerative disorders |
| US8889076B2 (en) * | 2008-12-29 | 2014-11-18 | Uop Llc | Fluid catalytic cracking system and process |
-
2008
- 2008-01-04 GB GB0800390A patent/GB2456183A/en not_active Withdrawn
- 2008-12-17 HU HUE13152600A patent/HUE047214T2/hu unknown
- 2008-12-17 NZ NZ586648A patent/NZ586648A/xx unknown
- 2008-12-17 PL PL13152600T patent/PL2609928T3/pl unknown
- 2008-12-17 EP EP08869534.1A patent/EP2249848B1/en active Active
- 2008-12-17 CN CN200880125822.5A patent/CN101939017B/zh active Active
- 2008-12-17 EP EP16167562.4A patent/EP3095452B1/en active Active
- 2008-12-17 BR BRPI0821461A patent/BRPI0821461A8/pt not_active IP Right Cessation
- 2008-12-17 US US12/811,393 patent/US9017737B2/en active Active
- 2008-12-17 ES ES08869534.1T patent/ES2574155T3/es active Active
- 2008-12-17 PT PT131526006T patent/PT2609928T/pt unknown
- 2008-12-17 HU HUE16167562A patent/HUE046780T2/hu unknown
- 2008-12-17 CA CA2708921A patent/CA2708921C/en active Active
- 2008-12-17 MX MX2010007073A patent/MX2010007073A/es active IP Right Grant
- 2008-12-17 GB GB1012953.4A patent/GB2468828B/en active Active
- 2008-12-17 ES ES16167562T patent/ES2750728T3/es active Active
- 2008-12-17 WO PCT/GB2008/004217 patent/WO2009087351A1/en not_active Ceased
- 2008-12-17 ES ES13152600T patent/ES2751117T3/es active Active
- 2008-12-17 JP JP2010541094A patent/JP5409650B2/ja active Active
- 2008-12-17 PL PL16167562T patent/PL3095452T3/pl unknown
- 2008-12-17 RU RU2010132649/15A patent/RU2503448C2/ru active
- 2008-12-17 EP EP13152600.6A patent/EP2609928B1/en active Active
- 2008-12-17 PT PT161675624T patent/PT3095452T/pt unknown
- 2008-12-17 UA UAA201009705A patent/UA103472C2/uk unknown
- 2008-12-17 AU AU2008346285A patent/AU2008346285B2/en active Active
- 2008-12-17 KR KR1020107017111A patent/KR101631518B1/ko active Active
- 2008-12-24 CL CL2008003902A patent/CL2008003902A1/es unknown
- 2008-12-29 AR ARP080105764A patent/AR070063A1/es unknown
- 2008-12-31 TW TW097151656A patent/TWI519299B/zh not_active IP Right Cessation
- 2008-12-31 TW TW103121762A patent/TW201436791A/zh unknown
-
2009
- 2009-01-05 PE PE2009000002A patent/PE20091361A1/es not_active Application Discontinuation
- 2009-01-05 PE PE2014000565A patent/PE20141249A1/es not_active Application Discontinuation
-
2010
- 2010-07-04 IL IL206784A patent/IL206784A0/en active IP Right Grant
- 2010-07-29 ZA ZA2010/05443A patent/ZA201005443B/en unknown
- 2010-08-04 CO CO10095174A patent/CO6290695A2/es not_active Application Discontinuation
-
2012
- 2012-09-21 GB GBGB1216932.2A patent/GB201216932D0/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070063A1 (es) | Uso de cannabinoides combinados con un medicamento antipsicotico y metodos de tratamiento | |
| JP2011508765A5 (enExample) | ||
| SV2010003451A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| CL2012001397A1 (es) | Compuestos hetero-triciclicos condensados, moduladores de quinasa jak; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la prepararcion de medicamentos utiles en el tratamiento de enfermedades autoinmunes, cancer y trastornos del sistema nervioso central, entre otras. | |
| CO6251364A2 (es) | Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k | |
| AR073123A1 (es) | Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica | |
| BR112017006957A2 (pt) | formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína | |
| ECSP099451A (es) | Compuestos de urea policíclicos antibacterianos | |
| ECSP10010419A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos-211 | |
| UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| AR060631A1 (es) | Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k) | |
| BR112013004440A2 (pt) | método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral | |
| BRPI0912842A8 (pt) | composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina | |
| UY32315A (es) | Compuestos de piperidina y usos de los mismo-596 | |
| BR112013017750A2 (pt) | nanocápsulas com envoltório polimérico | |
| CO6710926A2 (es) | Compuestos de n-heteroarilo | |
| AR058338A1 (es) | Derivados de pirrol fusionado, composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la quinasa. | |
| AR060786A1 (es) | Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina | |
| Zhou et al. | Morusin inhibits the growth of human colorectal cancer HCT116-derived sphere-forming cells via the inactivation of Akt pathway | |
| FI3970707T3 (fi) | Kannabidivariinin käyttö skitsofrenian negatiivisten oireiden hoitoon | |
| SV2010003752A (es) | Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas | |
| UY32674A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
| UY31865A (es) | Derivados de urea heterocíclicos y métodos para la utilización de los mismos | |
| AR060730A1 (es) | Formulacion de medicamento liquida | |
| PA8824601A1 (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |